Jean-Claude Roujeau

Author PubWeight™ 68.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002 5.58
2 Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2007 3.58
3 Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2007 2.71
4 Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002 2.49
5 A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007 2.41
6 Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004 2.33
7 Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003 1.94
8 A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008 1.92
9 Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009 1.66
10 Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2011 1.60
11 Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009 1.53
12 Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003 1.53
13 Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002 1.35
14 Toxic epidermal necrolysis, DRESS, AGEP: do overlap cases exist? Orphanet J Rare Dis 2012 1.32
15 Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002 1.32
16 Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013 1.28
17 A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009 1.26
18 Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2010 1.22
19 Response to: mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2005 1.18
20 Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med 2013 1.15
21 Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol 2013 1.12
22 French people and skin diseases: results of a survey using a representative sample. Arch Dermatol 2003 1.11
23 Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004 1.09
24 Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011 1.07
25 Drug-induced skin, nail and hair disorders. Drug Saf 2007 1.07
26 Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006 1.04
27 Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 2005 1.02
28 Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 2002 0.99
29 In vivo confocal microscopic evaluation of corneal changes in chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Cornea 2009 0.98
30 Acute bacterial skin infections and cellulitis. Curr Opin Infect Dis 2007 0.96
31 Impact of STROBE statement publication on quality of observational study reporting: interrupted time series versus before-after analysis. PLoS One 2013 0.95
32 A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol 2010 0.93
33 Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis 2011 0.91
34 Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol 2010 0.88
35 Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol 2002 0.86
36 Pemphigus vulgaris: a case-based update. J Can Dent Assoc 2005 0.85
37 Successful treatment of nodular lymphangitis due to Mycobacterium chelonae in two immunosuppressed patients. Dermatol Online J 2011 0.84
38 Recurrent erythema multiforme in association with recurrent Mycoplasma pneumoniae infections. J Am Acad Dermatol 2007 0.84
39 Association analysis of drug metabolizing enzyme gene polymorphisms in AIDS patients with cutaneous reactions to sulfonamides. J Invest Dermatol 2005 0.82
40 Chronic granulomatous Mycobacterium avium skin pseudotumour. Lancet Infect Dis 2009 0.82
41 Atypical linear IgA dermatosis revealing angioimmunoblastic T-cell lymphoma. Arch Dermatol 2009 0.81
42 Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol 2011 0.81
43 Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res 2011 0.81
44 Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. Medicine (Baltimore) 2010 0.80
45 Severe and unrecognized dental abnormalities after drug-induced epidermal necrolysis. Arch Dermatol 2009 0.79
46 Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk? Drug Saf 2013 0.79
47 Denominations and classification of severe cutaneous adverse reactions to drugs: splitters versus mergers. Eur J Dermatol 2007 0.78
48 Neurological manifestations of polyarteritis nodosa associated with the antiphospholipid syndrome. Ann Med Interne (Paris) 2003 0.77
49 Possible relation of Tunisian pemphigus with traditional cosmetics: a multicenter case-control study. Am J Epidemiol 2002 0.77
50 Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009 0.77
51 Treatment of bullous pemphigoid. J Dermatol 2003 0.76
52 Vesiculopustules in adult-onset Still's disease. J Am Acad Dermatol 2006 0.76
53 Drug-induced epidermal necrolysis: Important new piece to end the puzzle. J Allergy Clin Immunol 2011 0.76
54 Minocycline-induced DRESS: evidence for accumulation of the culprit drug. Dermatology 2008 0.76
55 Cell-mediated immunologic mechanism and severity of TEN. Arch Dermatol 2005 0.75
56 [Use of high dose intravenous immunoglobulins in dermatology]. J Dtsch Dermatol Ges 2010 0.75
57 EMPACT syndrome. J Dtsch Dermatol Ges 2005 0.75
58 Intravenous immunoglobulins in the treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 2003 0.75
59 Prognostic value of histologic features of toxic epidermal necrolysis. J Am Acad Dermatol 2011 0.75
60 Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. J Am Acad Dermatol 2011 0.75
61 Nosocomial disseminated Mycobacterium chelonae infection in an immunocompromised patient. Eur J Dermatol 2010 0.75
62 Septic facial vein thrombosis due to Panton-Valentine leukocidin-positive Staphylococcus aureus. Arch Dermatol 2009 0.75
63 Terbinafine-induced subacute cutaneous lupus erythematosus. Dermatology 2006 0.75
64 The role of topical corticosteroids in bullous pemphigoid in the elderly. Drugs Aging 2005 0.75
65 Lack of a specific humoral autoreactivity in sera from patients with early erythema exsudativum multiforme majus. J Invest Dermatol 2013 0.75
66 Severe sialadenitis: a new complication of drug reaction with eosinophilia and systemic symptoms. J Am Acad Dermatol 2004 0.75
67 [Role of the nurse in care of bullous pemphigoid]. Rev Infirm 2010 0.75